Objective
Preparations derived from Cannabis nativa have been used as medicines throughout Europe and Asiasince the earliest written records, especially in the treatment of pain and inflammation. A number ofstudies have focused on specific aspects of Cannabis and its constituents, but very little commercialdevelopment activity has focused on the production of high quality, high value, standardised extracts(preferably low in the psychoactive constituent THC) which are orally active and suitable for clinicaluse. A recent large-scale clinical trial of cannabis in over 600 patients with multiple sclerosis, whilstgiving equivocal results on the amelioration of muscle spasm, showed significant effects on relievingthe associated pain. It is generally accepted that refined extracts of Cannabis, rather than singleconstituents, are more likely to yield an economically viable product. Commercial ventures have so farfocused purely on selecting 'appropriate' cultivars to protect individual patents, rather than establishingproper scientific criteria based on chemical and pharmacological requirements for developingtherapeutically active preparations. Production methods for establishing suitable standardized extracts,and subsequent pharmaceutical formulations (which would result in a valuable IP for any company),have not yet been at the centre of any serious R&D attention. This consortium of SMEs and universitiesintends to develop such extracts using in vitro and in vivo pharmacological methods, as well as ametabolomic profiling of the final products focusing particularly on arthritis and migraine. These aretwo therapeutic areas of pain and inflammation for which both anecdotal and scientific evidencealready exists, but which have not yet resulted in appropriate development of a commercial product.The relevance of these conditions is highlighted by the fact that in the ED the standard prevalence ofmigraine is 19.6% with a gender incidence of 1:2.4 (men: women), an average age of 46.1 yea
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine rheumatology
- medical and health sciences basic medicine neurology multiple sclerosis
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Data not available
Coordinator
LONDON
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.